Does hair thinning at week two of orforglipron usually resolve without a dose change?

For reference: hair thinning · two · orforglipron.

I have done this once and I suspect I got away with it rather than got it right.

For context: I keep records of every batch, every lot number and every result, so an answer that requires me to track something is fine.

What does a defensible version of this look like in practice?

Patterned rather than diffuse loss is a different condition and points elsewhere.

Adequate protein matters. Hair is largely keratin, and follicles are among the most metabolically active tissues, so they are early casualties of a substantial protein shortfall.

Recovery follows the same timeline in reverse: shedding stops within a few months of the trigger resolving, and visible density returns over six to twelve months as regrowth reaches length.

Telogen effluvium following rapid weight loss is well documented in the dermatological literature, including extensive description after bariatric surgery.

Protein intake is the modifiable nutritional factor worth attending to.

Stated carefully, this is one of the most distressing reported effects and one of the most reliably temporary.

In telogen effluvium a stressor shifts a large fraction of follicles from anagen into telogen simultaneously. Because telogen lasts around two to three months, the shed appears two to four months after the trigger rather than during it.

Worth being precise here: nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.

The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.

Nothing here is medical advice.

The trigger is the rate of loss, not the compound. Slowing it helps future follicles.

The short version: diffuse rather than patterned, delayed rather than immediate, self-limiting, and driven by the rate of loss rather than by the compound.

The trigger in this context is the rate of weight loss and the associated nutritional deficit, not a pharmacological property. The same phenomenon is well documented after bariatric surgery, illness and childbirth.

Low ferritin is associated with increased shedding in observational studies at thresholds above those used to define anaemia.

Research-use compounds are not approved for human use.

Check ferritin, thyroid and vitamin D once, then stop investigating.

Answer first: the pattern reported here is telogen effluvium — a diffuse shed triggered by a physiological stressor — and rapid weight loss is a well-established trigger for it.

Worth checking: ferritin, thyroid function and vitamin D. Low ferritin in particular is associated with shedding at levels that are not low enough to cause anaemia.

The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.

Supplementing without a measured deficiency has no evidence behind it here and is not harmless at high doses.

Diffuse and delayed means telogen effluvium. Patterned means something else.

edited 27 Feb 2025 by Dr_Nadia_Farsi — added the method parameters